A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The study will generate data on safety, tolerability and pharmacokinetics after multiple
daily doses of CK-2017357 in patients with ALS. Patients will be randomized into one of four
different treatment groups, receiving daily oral doses of either placebo, 125 mg, 250 mg, or
375 mg of CK-2017357 for 14 days.